Trials / Unknown
UnknownNCT04009317
Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)
A Multicenter, Randomized, Open-label Study to Evaluate the Efficacy and Safety of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 260 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of TQ-B3139 versus crizotinib in subjects with ALK-positive NSCLC that have received one chemotherapy regimen and have not received ALK inhibitor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQ-B3139 | a multi-target protein kinase inhibitor. |
| DRUG | Crizotinib | a multi-target protein kinase inhibitor. |
Timeline
- Start date
- 2019-08-13
- Primary completion
- 2021-10-30
- Completion
- 2022-04-30
- First posted
- 2019-07-05
- Last updated
- 2019-10-30
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04009317. Inclusion in this directory is not an endorsement.